Free Trial
NASDAQ:PSTV

Plus Therapeutics (PSTV) Stock Price, News & Analysis

$2.10
-0.08 (-3.67%)
(As of 03:50 PM ET)
Today's Range
$2.04
$2.19
50-Day Range
$1.60
$2.32
52-Week Range
$0.97
$4.45
Volume
37,671 shs
Average Volume
57,044 shs
Market Capitalization
$11.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Plus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
281.0% Upside
$8.00 Price Target
Short Interest
Healthy
1.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Plus Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$55,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.49 out of 5 stars

Medical Sector

472nd out of 921 stocks

Surgical & Medical Instruments Industry

58th out of 100 stocks

PSTV stock logo

About Plus Therapeutics Stock (NASDAQ:PSTV)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Stock Price History

PSTV Stock News Headlines

Plus: Q1 Earnings Snapshot
Plus Therapeutics Inc. Q1 Loss Decreases, Beats Estimates
Plus Therapeutics, Inc. (PSTV)
See More Headlines
Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
5/21/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PSTV
Employees
20
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+286.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,320,000.00
Net Margins
-193.49%
Pretax Margin
-193.49%

Debt

Sales & Book Value

Annual Sales
$4.91 million
Book Value
($0.30) per share

Miscellaneous

Free Float
5,572,000
Market Cap
$11.80 million
Optionable
Not Optionable
Beta
0.55

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Marc H. Hedrick M.B.A. (Age 61)
    M.D., President, CEO & Director
    Comp: $945.34k
  • Mr. Andrew J. Sims CPA (Age 51)
    VP of Finance & CFO
    Comp: $498.51k
  • Dr. Norman D. LaFrance FACNP (Age 76)
    FACP, M.D., Chief Medical Officer & Senior VP
    Comp: $646.02k
  • Ms. Desiree Smith (Age 60)
    Corporate Controller, Principal Financial & Accounting Officer
  • Dr. John K. Fraser (Age 63)
    Chief Scientist

PSTV Stock Analysis - Frequently Asked Questions

Should I buy or sell Plus Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTV shares.
View PSTV analyst ratings
or view top-rated stocks.

What is Plus Therapeutics' stock price target for 2024?

1 brokers have issued 12 month price targets for Plus Therapeutics' stock. Their PSTV share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 281.0% from the stock's current price.
View analysts price targets for PSTV
or view top-rated stocks among Wall Street analysts.

How have PSTV shares performed in 2024?

Plus Therapeutics' stock was trading at $1.7501 at the beginning of 2024. Since then, PSTV stock has increased by 20.0% and is now trading at $2.10.
View the best growth stocks for 2024 here
.

When is Plus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our PSTV earnings forecast
.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) posted its earnings results on Wednesday, May, 15th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.34. The firm had revenue of $1.68 million for the quarter. Plus Therapeutics had a negative net margin of 193.49% and a negative trailing twelve-month return on equity of 805.57%. During the same quarter last year, the business posted ($2.10) EPS.

When did Plus Therapeutics' stock split?

Plus Therapeutics shares reverse split on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY).

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSTV) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners